selectively destroys these central regions, thus turning a non curative treatment into a curative one.
The authors hypothesized that because adhesion of leukemic cells to vascular cells may confer resistance to chemotherapeutic agents, treatment with CA4P
would promote leukemic cell death by disrupting leukemic cell cytoskeletal stability and interfering with vascular cell interactions.
In the publication, the researchers point out that data from the clinical studies suggest that CA4P
reduces tumor blood supply at doses that are safe and well tolerated.
Anderson Cancer Center in Houston, TX and colleagues report that both triple-drug combinations incorporating CA4P
showed positive results, as determined by tumor volume and weight assessments, in mouse xenograft models of ATC utilizing two human ATC cell lines.
OXiGENE is thrilled that Bristol-Myers Squibb has shown such interest in CA4P
and we at OXiGENE are confident that this IND submission will lead to the rapid development of the first effective anti-vascular targeting agent with therapeutic effect in existing tumor vasculature," said Bjorn Nordenvall, Chairman and Chief Executive Officer of OXiGENE.
The first abstract reports for the first time full data from a randomized Phase II trial of Combretastatin A4 Phosphate / CA4P
(trademarked by OXiGENE as ZYBRESTAT[TM]) in combination with paclitaxel and carboplatin.
In the terms of the deal last December, OXiGENE retained all non-systemic rights for the usage of CA4P
, which is currently undergoing pre-clinical studies in ocular diseases in the laboratory of Donald Armstrong, Ph.
MMD-213 was a Phase II, double-masked (physician and subject), dose-ranging, multi-center study designed to evaluate the safety and efficacy of intravenous CA4P
for treating subfoveal choroidal neovascularization in subjects with pathologic myopia.
In March 2006, OXiGENE announced the completion of patient enrollment in a Phase II clinical trial evaluating CA4P
with chemotherapy in imageable solid tumors.
This was a randomized open-label study of intravenous CA4P
administered at 45 or 63 mg/m2 followed by paclitaxel and carboplatin in 13 patients.
The Company will commence a Phase Ib clinical study to evaluate CA4P
in combination therapy with Avastin(R) (Bevacizumab), a drug that is owned and marketed by Genentech .
Driscoll built strong relationships with institutional investors, investment banks and research analysts and successfully recapitalized the company through private and public financings, enabling the company to advance its lead oncology investigational drug CA4P
from Phase 1 to Phase 3 clinical development.